Specializing in the discovery, development, and commercialization of groundbreaking treatments, La Jolla Pharmaceutical is dedicated to improving the lives of patients with life-threatening conditions. Their portfolio includes a first-in-class inhibitor targeting galectin-3, a molecule associated with chronic organ failure and cancer, as well as a natural peptide for treating hepatorenal syndrome. Additionally, the company offers an angiotensin II formulation for blood pressure regulation, a hepcidin formulation for iron metabolism regulation, and an FDA-approved antibiotic.